These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

232 related articles for article (PubMed ID: 25678055)

  • 1. Transcriptional Profiling of Laser Capture Microdissected Subpopulations of the Osteoblast Lineage Provides Insight Into the Early Response to Sclerostin Antibody in Rats.
    Nioi P; Taylor S; Hu R; Pacheco E; He YD; Hamadeh H; Paszty C; Pyrah I; Ominsky MS; Boyce RW
    J Bone Miner Res; 2015 Aug; 30(8):1457-67. PubMed ID: 25678055
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Time-dependent cellular and transcriptional changes in the osteoblast lineage associated with sclerostin antibody treatment in ovariectomized rats.
    Taylor S; Ominsky MS; Hu R; Pacheco E; He YD; Brown DL; Aguirre JI; Wronski TJ; Buntich S; Afshari CA; Pyrah I; Nioi P; Boyce RW
    Bone; 2016 Mar; 84():148-159. PubMed ID: 26721737
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Temporal changes in systemic and local expression of bone turnover markers during six months of sclerostin antibody administration to ovariectomized rats.
    Stolina M; Dwyer D; Niu QT; Villasenor KS; Kurimoto P; Grisanti M; Han CY; Liu M; Li X; Ominsky MS; Ke HZ; Kostenuik PJ
    Bone; 2014 Oct; 67():305-13. PubMed ID: 25093263
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Differential time-dependent transcriptional changes in the osteoblast lineage in cortical bone associated with sclerostin antibody treatment in ovariectomized rats.
    Taylor S; Hu R; Pacheco E; Locher K; Pyrah I; Ominsky MS; Boyce RW
    Bone Rep; 2018 Jun; 8():95-103. PubMed ID: 29955627
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Differential temporal effects of sclerostin antibody and parathyroid hormone on cancellous and cortical bone and quantitative differences in effects on the osteoblast lineage in young intact rats.
    Ominsky MS; Brown DL; Van G; Cordover D; Pacheco E; Frazier E; Cherepow L; Higgins-Garn M; Aguirre JI; Wronski TJ; Stolina M; Zhou L; Pyrah I; Boyce RW
    Bone; 2015 Dec; 81():380-391. PubMed ID: 26261096
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sclerostin Antibody Administration Converts Bone Lining Cells Into Active Osteoblasts.
    Kim SW; Lu Y; Williams EA; Lai F; Lee JY; Enishi T; Balani DH; Ominsky MS; Ke HZ; Kronenberg HM; Wein MN
    J Bone Miner Res; 2017 May; 32(5):892-901. PubMed ID: 27862326
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sclerostin antibody preserves the morphology and structure of osteocytes and blocks the severe skeletal deterioration after motor-complete spinal cord injury in rats.
    Qin W; Li X; Peng Y; Harlow LM; Ren Y; Wu Y; Li J; Qin Y; Sun J; Zheng S; Brown T; Feng JQ; Ke HZ; Bauman WA; Cardozo CC
    J Bone Miner Res; 2015 Nov; 30(11):1994-2004. PubMed ID: 25974843
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Progressive increases in bone mass and bone strength in an ovariectomized rat model of osteoporosis after 26 weeks of treatment with a sclerostin antibody.
    Li X; Niu QT; Warmington KS; Asuncion FJ; Dwyer D; Grisanti M; Han CY; Stolina M; Eschenberg MJ; Kostenuik PJ; Simonet WS; Ominsky MS; Ke HZ
    Endocrinology; 2014 Dec; 155(12):4785-97. PubMed ID: 25259718
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Suppression of Sclerostin Alleviates Radiation-Induced Bone Loss by Protecting Bone-Forming Cells and Their Progenitors Through Distinct Mechanisms.
    Chandra A; Lin T; Young T; Tong W; Ma X; Tseng WJ; Kramer I; Kneissel M; Levine MA; Zhang Y; Cengel K; Liu XS; Qin L
    J Bone Miner Res; 2017 Feb; 32(2):360-372. PubMed ID: 27635523
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibition of sclerostin by systemic treatment with sclerostin antibody enhances healing of proximal tibial defects in ovariectomized rats.
    McDonald MM; Morse A; Mikulec K; Peacock L; Yu N; Baldock PA; Birke O; Liu M; Ke HZ; Little DG
    J Orthop Res; 2012 Oct; 30(10):1541-8. PubMed ID: 22457198
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dampening of the bone formation response following repeat dosing with sclerostin antibody in mice is associated with up-regulation of Wnt antagonists.
    Holdsworth G; Greenslade K; Jose J; Stencel Z; Kirby H; Moore A; Ke HZ; Robinson MK
    Bone; 2018 Feb; 107():93-103. PubMed ID: 29129759
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rictor is required for optimal bone accrual in response to anti-sclerostin therapy in the mouse.
    Sun W; Shi Y; Lee WC; Lee SY; Long F
    Bone; 2016 Apr; 85():1-8. PubMed ID: 26780446
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinically Relevant Doses of Sclerostin Antibody Do Not Induce Osteonecrosis of the Jaw (ONJ) in Rats with Experimental Periodontitis.
    Hadaya D; Gkouveris I; Soundia A; Bezouglaia O; Boyce RW; Stolina M; Dwyer D; Dry SM; Pirih FQ; Aghaloo TL; Tetradis S
    J Bone Miner Res; 2019 Jan; 34(1):171-181. PubMed ID: 30184271
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Reactivation of Bone Lining Cells are Attenuated Over Repeated Anti-sclerostin Antibody Administration.
    Hong AR; Yang JY; Lee JY; Suh J; Lee YS; Kim JE; Kim SW
    Calcif Tissue Int; 2022 Nov; 111(5):495-505. PubMed ID: 35925416
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sclerostin Antibody Augments the Anabolic Bone Formation Response in a Mouse Model of Mechanical Tibial Loading.
    Morse A; Schindeler A; McDonald MM; Kneissel M; Kramer I; Little DG
    J Bone Miner Res; 2018 Mar; 33(3):486-498. PubMed ID: 29090474
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sclerostin Antibody Treatment Increases Bone Formation, Bone Mass, and Bone Strength of Intact Bones in Adult Male Rats.
    Suen PK; Zhu TY; Chow DH; Huang L; Zheng LZ; Qin L
    Sci Rep; 2015 Oct; 5():15632. PubMed ID: 26494536
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Time course of disassociation of bone formation signals with bone mass and bone strength in sclerostin antibody treated ovariectomized rats.
    Ma YL; Hamang M; Lucchesi J; Bivi N; Zeng Q; Adrian MD; Raines SE; Li J; Kuhstoss SA; Obungu V; Bryant HU; Krishnan V
    Bone; 2017 Apr; 97():20-28. PubMed ID: 27939957
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tissue-level mechanisms responsible for the increase in bone formation and bone volume by sclerostin antibody.
    Ominsky MS; Niu QT; Li C; Li X; Ke HZ
    J Bone Miner Res; 2014 Jun; 29(6):1424-30. PubMed ID: 24967455
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sclerostin antibody treatment increases bone formation, bone mass, and bone strength in a rat model of postmenopausal osteoporosis.
    Li X; Ominsky MS; Warmington KS; Morony S; Gong J; Cao J; Gao Y; Shalhoub V; Tipton B; Haldankar R; Chen Q; Winters A; Boone T; Geng Z; Niu QT; Ke HZ; Kostenuik PJ; Simonet WS; Lacey DL; Paszty C
    J Bone Miner Res; 2009 Apr; 24(4):578-88. PubMed ID: 19049336
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Suppression of Sost/Sclerostin and Dickkopf-1 Augment Intervertebral Disc Structure in Mice.
    Kroon T; Bhadouria N; Niziolek P; Edwards D; Choi R; Clinkenbeard EL; Robling A; Holguin N
    J Bone Miner Res; 2022 Jun; 37(6):1156-1169. PubMed ID: 35278242
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.